Sutro Biopharma (STRO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $15.34 (-0.90%), Market cap $0.52B, 52-week low–high $0.68 ~ $40.91.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II
Financial statements, price targets, institutional (13F) holdings and related news for Sutro Biopharma are updated in real time on BlackAll Trade.
Sutro Biopharma trades at $15.34 (-0.90%). Real-time quotes and charts are available on BlackAll Trade.
Sutro Biopharma has a market cap of about $0.52B.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein syn